Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
Immunogenicity
Non-clinical
Pneumococcal conjugate vaccine
Serotypes
Streptococcus pneumoniae
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
27 05 2021
27 05 2021
Historique:
received:
18
10
2020
revised:
16
03
2021
accepted:
19
03
2021
pubmed:
10
5
2021
medline:
28
5
2021
entrez:
9
5
2021
Statut:
ppublish
Résumé
Despite widespread utilization of pneumococcal conjugate vaccines (PCVs) and the resultant disease reduction, the development of PCVs containing additional serotypes remains a public health priority due to serotype replacement and the resultant shift to non-vaccine containing serotypes. However, incorporating additional serotypes to existing PCVs using conventional technologies has proven problematic. Immune responses to individual serotypes have consistently decreased as more polysaccharide-conjugates are added due to carrier suppression. Using our proprietary cell-free protein synthesis (CFPS) platform, we have successfully produced eCRM® based on the CRM
Identifiants
pubmed: 33965258
pii: S0264-410X(21)00374-1
doi: 10.1016/j.vaccine.2021.03.070
pii:
doi:
Substances chimiques
Antibodies, Bacterial
0
Carrier Proteins
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3197-3206Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [All authors are employees or paid consultants for Vaxcyte, Inc.]